CC
SPRY icon

Cannell Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Cannell Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,402
Closed -$80.2K – 93
2022
Q4 		$80.2K Hold
9,402
– – 0.02% 62
2022
Q3 		$50K Buy
9,402
+6,833
+266% +$33.7K 0.01% 67
2022
Q2 		$11K Buy
+2,569
New +$8.96K ﹤0.01% 79

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell Capital's SPRY Position: Q1 2023 in Review

Cannell Capital sold out of ARS Pharmaceuticals (SPRY) in Q1 2023, closing a stake of 9,402 shares — an estimated $80.2K sold.

Cannell Capital first reported a position in SPRY in Q2 2022 and held it in 3 quarters. The position peaked at $80.2K in Q4 2022. 89 funds tracked by Wall St. Rank hold SPRY as of Q1 2023.

  • Cannell Capital reported no remaining ARS Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cannell Capital sold 9,402 ARS Pharmaceuticals shares in Q1 2023, an estimated $80.2K.
  • Cannell Capital first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Cannell Capital's ARS Pharmaceuticals position peaked at $80.2K in Q4 2022.
  • 89 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2023.

Based on Cannell Capital's 13F filing for Q1 2023, filed 15 May 2023.